idc btig estim compani document
million except per share amount
solid perform despit high expect reiter buy
rais pt
slightli better consensu despit data center outag end june
push order placement releas june
also note prior full year consensu high-end prior guidanc
top bottom line data center outag neg impact organ revenu
growth approxim also ep complet resolv
end impact full year expect tmo organ
revenu growth guidanc full year remain y/i although outlook
rais slightli ep guidanc rais midpoint
biopharma china end market remain bright spot double-digit mid-teen
growth respect rest end market continu trend line
manag prior expect remain well trajectori
achiev long-term growth target view annual growth
organ revenu ep compani continu strengthen
strateg competit posit capit fastest grow
segment within life scienc tool diagnost market furthermor
believ tmo capit deploy potenti billion next three year
provid meaning ep leverag fulli factor consensu
estim manag comment pipelin quit activ
current revis pt base price-to-earnings line
averag peer group larg reflect recent multipl expans
model updat revenu ep estim y/i vs
prior y/i vs prior
revenu ep estim y/i vs bn prior
valuat pt base price-to-earnings
largest compani life scienc tool industri better posit ever view
capit fastest grow market segment well take share competitor leverag
 budget economi scale strateg invest made last sever year high growth area
continu priorit oper effici initi better ever organ revenu growth
outlook capit deploy potenti ahead believ minimum line price-to-earnings multipl
warrant vs peer group life scienc tool compani
financi result midpoint compani guidanc
perform midpoint compani three-year
includ potenti futur acquisit gener in-lin
guidanc includ addit leverag full capit deploy
thermo fisher scientif
largest compani life scienc
tool industri revenu
reagent chemic suppli
servic research biopharma
industri diagnost clinic
appli market thermo also
provid scientif product
channel busi
thermo headquart
better-than-expect nt lt financi perform
faster-than-expect capit deploy
worse-than-expect nt lt financi perform
signific and/or prolong deterior demand across tmo end
exhibit varianc million except per share data
exhibit end market observ geographi growth constant currenc
ht
hsd msd
hsd hsd
lt mt fy
china
fy
double-digit
india fy
msd hsd
stronger
china mt
actualstreet estimate btig chang profit gross margin incom oper margin rate incom chang
exhibit end market observ end market growth constant currenc
across
grew
growth
growth
europ
grew
across
across
saw
increas
flow
fund
across
fy
across
fy
fy
bio-
pharma
strength
condit
america
strength
also
demand
analysi
across
strength
north
europ
strength
fy
grew
across
serv
increas outlook
benefit
time
headwind
growth around
averag full year
acquisit
complet
bioprocess off-set
divestitur creat
y/i headwind
headwind
revenu major
expect
divestitur
anatom patholog
incl bp headwind
tariff reflect full
tariff
current place
contribut
acquisit brammer
expect close
fx brammer
headwind fx
headwind
assum debt
assum debt
repay
repay
headwind
incl dilut
sale anatom
incl fx headwind
incl accret
brammer acquisit
incl fx headwind
updat
incl dilut
sale anatom
accret advanc
incl headwind tariff
unchang
share
benefit non-
oper fx
increas
midpoint consist
stronger
better fx
time
incl fx headwind
phase
mirror
expect off-set increment
invest strong
expans invest
complet earli
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
